Literature DB >> 11469474

Estimating the costs of job related arthritis.

J P Leigh1, W Seavey, B Leistikow.   

Abstract

OBJECTIVE: To present the first estimate of the costs of job related osteoarthritis (OA) in the USA.
METHODS: Data were drawn from national data sets collected by the US Bureau of Labor Statistics, the US National Center for Health Statistics, and existing cost estimates for arthritis in the literature. We used proportional attributable risk (PAR) models to estimate the percentage of acute and repetitive injuries resulting in OA. These PAR vary between men and women. We used the human capital method that decomposes costs into direct categories such as medical expense and indirect categories such as lost earnings.
RESULTS: We estimate job related OA costs US$3.41 to 13.23 billion per year (1994 dollars). Our point estimate is that job related OA contributes about 9% ($8.3 billion) to the total costs for all OA. About 51% of job related costs result from medical costs and 49% from lost productivity at work and at home. These costs are likely to underestimate the true burden since costs of pain and suffering as well as costs to family members and others who provide home care are ignored.
CONCLUSION: The cost of job related arthritis is significant and has implications for both clinical and public policy. Depending on the PAR selected, job related arthritis is at least as costly as job related renal and neurological disease combined, and is on a par with the costs of job related chronic obstructive pulmonary disease and all asthma, whether job related or not.

Entities:  

Mesh:

Year:  2001        PMID: 11469474

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  16 in total

Review 1.  Effects of exercise and physical activity on knee osteoarthritis.

Authors:  Stephan Esser; Allison Bailey
Journal:  Curr Pain Headache Rep       Date:  2011-12

2.  Vimovo™: (naproxen/esomeprazole magnesium) delayed-release tablets.

Authors: 
Journal:  P T       Date:  2010-09

3.  Occupational disease and workers' compensation: coverage, costs, and consequences.

Authors:  J Paul Leigh; John A Robbins
Journal:  Milbank Q       Date:  2004       Impact factor: 4.911

4.  Prognostic factors for sustained work participation in early osteoarthritis: a follow-up study in the Cohort Hip and Cohort Knee (CHECK).

Authors:  Hendrik J Bieleman; Michiel F Reneman; K Wiepke Drossaers-Bakker; Johan W Groothoff; Frits G J Oosterveld
Journal:  J Occup Rehabil       Date:  2013-03

5.  Significance of C-reactive protein in osteoarthritis and total knee arthroplasty outcomes.

Authors:  Jessica W Smith; Thomas B Martins; Evelyn Gopez; Troy Johnson; Harry R Hill; Thomas D Rosenberg
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-10       Impact factor: 5.346

6.  Patient disease perceptions and coping strategies for arthritis in a developing nation: a qualitative study.

Authors:  Nina N Niu; Aileen M Davis; Laura M Bogart; Thomas S Thornhill; Luis Alcantara Abreu; Roya Ghazinouri; Jeffrey N Katz
Journal:  BMC Musculoskelet Disord       Date:  2011-10-10       Impact factor: 2.362

Review 7.  Occupational and genetic risk factors for osteoarthritis: a review.

Authors:  Berran Yucesoy; Luenda E Charles; Brent Baker; Cecil M Burchfiel
Journal:  Work       Date:  2015-01-01

8.  A puzzle assembly strategy for fabrication of large engineered cartilage tissue constructs.

Authors:  Adam B Nover; Brian K Jones; William T Yu; Daniel S Donovan; Jeremy D Podolnick; James L Cook; Gerard A Ateshian; Clark T Hung
Journal:  J Biomech       Date:  2016-02-09       Impact factor: 2.712

9.  Sex differences in spinal osteoarthritis in humans and rhesus monkeys (Macaca mulatta).

Authors:  Andrea E Duncan; Ricki J Colman; Patricia A Kramer
Journal:  Spine (Phila Pa 1976)       Date:  2012-05-15       Impact factor: 3.468

Review 10.  A Mechanism-Based Approach to the Management of Osteoarthritis Pain.

Authors:  Ezra Cohen; Yvonne C Lee
Journal:  Curr Osteoporos Rep       Date:  2015-12       Impact factor: 5.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.